Bone News and Research

RSS

Unigene Labs reports financial results for three months ended June 30, 2009

Revenue for the three months ended June 30, 2009 was $4,297,000, compared to $4,978,000 for the three months ended June 30, 2008. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $3,807,000 for the three months ended June 30, 2009, and $4,110,000 for the three months ended June 30, 2008.

11 Aug 2009

Metabolic bone disease in cirrhosis patients

Long-standing liver disease has long been recognized to result in fragile bones with increased risk of fractures. In various international studies, the overall incidence has varied from 11% to 48%, with a fracture rate of 3%-44%.

10 Aug 2009

Cephalon, Inc. completes acquisition of Arana Therapeutics

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of all of the outstanding ordinary shares of Australian biotechnology company, Arana Therapeutics Limited. As a result of the acquisition, Arana is now a wholly-owned subsidiary of Cephalon.

10 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Gtx, Inc. reports Q2 2009 results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2009. The net loss for the second quarter and six months ended June 30, 2009 was $11.3 million and $22.6 million, respectively, compared with a net loss of $13.2 million and $26.0 million for the same periods in 2008. At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million.

10 Aug 2009

Need to rethink pros and cons of limb-sparing surgery and amputation

Limb-sparing surgery, which has been taking the place of amputation for bone and soft tissue sarcomas of the lower limb in recent years, may not provide much or even any additional benefit to patients according to a new review. The analysis, published in the September 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, indicates that patients and physicians should rethink the pros and cons of limb-sparing surgery and amputation.

10 Aug 2009

Stroke doubles patients' risk of breaking a hip or femur

Stroke survivors have about twice the risk of breaking a hip or femur compared to those without stroke - and the risk is even greater for younger patients, women and those with recent strokes, Dutch researchers report in Stroke: Journal of the American Heart Association.

6 Aug 2009

Discovery of common trigger in cancer and normal stem cell reproduction

Researchers at Stanford University School of Medicine have discovered, for the first time, a common molecular pathway that is used by both normal stem cells and cancer stem cells when they reproduce themselves.

6 Aug 2009

Thermogenesis expands collaboration with Celling Technologies

ThermoGenesis has announced an expanded collaboration with Celling Technologies, a subsidiary of SpineSmith, LLC, related to the Company's bone marrow products, MXP(TM) MarrowXpress(TM) and Res-Q(TM) 60 BMC. Celling is a leading distributor of orthopedic products, based in Texas.

6 Aug 2009

Percutaneous vertebroplasty exposed as ineffective

A world-first study involving Monash University and the Cabrini Research Institute in Melbourne has revealed the injection of bone cement into broken vertebrae is not an effective treatment for patients suffering painful osteoporotic fractures.

6 Aug 2009

Comparative effectiveness studies raise questions about vertebroplasty back pain treatment

New studies on treating back pain from a fractured spine could call more attention to the type of comparative effectiveness research health policy experts and President Barack Obama have embraced in their quest to increase quality of care while lowering costs.

6 Aug 2009

Spectrum Pharmaceuticals acquires rights and IP for Renazorb

Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.

6 Aug 2009

Genzyme’s Mozobil approved in Europe

Genzyme Corporation announced today that the European Commission has granted marketing authorization for Mozobil ® (plerixafor injection), providing a significant new option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.

6 Aug 2009

Discovery of new gene mutations linked to leukemia

Decoding the complete DNA of cancer patients is giving scientists at Washington University School of Medicine in St. Louis a clearer picture of the complexity of the disease and allowing them to see intriguing and unexpected genetic relationships among patients.

5 Aug 2009

World shortage of molybdenum may hinder nuclear medicine services

Problems with the world production and supply of molybdenum are leading to shortages of radioisotopes for nuclear medicine imaging tests, according to an editorial in the journal Nuclear Medicine Communications, official journal of the British Nuclear Medicine Society (BNMS).

5 Aug 2009

New understanding on Gleevec's limitations

University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.

4 Aug 2009

$Hip and back fractures increase mortality rates in Seniors$

Hip and back fractures increase mortality rates in Seniors

If you are 50 or older and you break your hip, you have a one in four chance of dying within five years. Break your back, and you have a one in six chance of dying that soon, says a McMaster University study.

4 Aug 2009

Flaw in bone's material leads to disease

The weak tendons and fragile bones characteristic of osteogenesis imperfecta, or brittle bone disease, stem from a genetic mutation that causes the incorrect substitution of a single amino acid in the chain of thousands of amino acids making up a collagen molecule, the basic building block of bone and tendon.

4 Aug 2009

Discovery of novel tumor suppressor

La Jolla Institute for Allergy & Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia.

4 Aug 2009

Will emphasis on prevention bring health costs down?

If there is one thing that both parties can agree on in the health overhaul debate, it’s the need to build a health system that promotes prevention rather than just manages disease.

4 Aug 2009